US20240148657
2024-05-09
Human necessities
A61K9/2095
The patent application focuses on utilizing fused filament fabrication (FFF) 3D printing technology to create solid dosage forms, particularly pharmaceutical tablets. By employing novel printing filaments that contain active ingredients, this method enables robust production of various formulations directly from a 3D printer. This innovation allows for personalized medicine to be produced on-site in pharmacies, catering to individual patient needs.
The solid dosage form printing apparatus consists of several key components:
Traditional manufacturing of solid dosage forms often requires large-scale production and complex processes, limiting customization and flexibility. The described method addresses these challenges by allowing for on-demand production of customized doses with minimal input variables. This results in higher active ingredient concentrations, improved stability of materials, and enhanced aesthetic customization without compromising quality or efficacy.
The invention includes purpose-built software for operating the printing apparatus and systems for real-time monitoring of multiple printers. This facilitates easy detection of malfunctions, supporting regulatory approval processes. Such compliance is crucial for ensuring the safety and effectiveness of personalized medicines produced via this innovative method.
The ability to produce solid dosage forms on-demand has significant implications for healthcare. It not only enhances patient compliance through customizable medications but also streamlines prototyping and formulation research in the pharmaceutical industry. This technology could revolutionize how medications are prescribed and dispensed, making treatments more accessible and tailored to individual patient requirements.